CLDN18.2 CAR T cells for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must have moderate to high levels of a protein called CLDN18.2.
- Your cancer must have spread or come back and not responded to standard treatments.
- You must be able to take care of yourself (ECOG 0 or 1).
- Your major organs and bone marrow must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
This trial tests a new type of immune therapy called CAR-T cells that target a protein called Claudin18.2 found on some solid tumors. The goal is to see if it can help shrink tumors in people who have already tried other treatments.
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
This trial tests a new treatment called anti-CDH17 CAR-T cells for people with advanced solid tumors that are CDH17-positive. The therapy uses your own immune cells, modified to target and destroy cancer cells, and aims to help when other treatments have stopped working.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This trial tests a new type of cell therapy (CT041) given after surgery and chemotherapy to prevent stomach cancer from coming back. It is for people whose tumors have a specific protein (CLDN18.2) and who have already had standard treatment.
Hear when a new CLDN18.2 Positive Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.